Pages that link to "Q38949770"
Jump to navigation
Jump to search
The following pages link to Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy (Q38949770):
Displaying 29 items.
- Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens (Q26774913) (← links)
- Immunogenic targets for specific immunotherapy in multiple myeloma (Q26859007) (← links)
- Immunotherapy strategies for multiple myeloma: the present and the future (Q27021939) (← links)
- Development of Novel Immunotherapies for Multiple Myeloma (Q28066890) (← links)
- Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma (Q28296718) (← links)
- Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers (Q33555751) (← links)
- Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. (Q33691970) (← links)
- High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survival (Q35144956) (← links)
- A Panel of Cancer Testis Antigens and Clinical Risk Factors to Predict Metastasis in Colorectal Cancer (Q35623585) (← links)
- Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow (Q35834665) (← links)
- Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy. (Q35846167) (← links)
- Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer (Q35852265) (← links)
- European perspective on multiple myeloma treatment strategies: update following recent congresses (Q35989943) (← links)
- An Optimization-Driven Analysis Pipeline to Uncover Biomarkers and Signaling Paths: Cervix Cancer (Q36069642) (← links)
- Cancer-testis antigen expression and immunogenicity in AL amyloidosis (Q36289604) (← links)
- MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer. (Q36579158) (← links)
- High expression levels of MAGE-A9 are correlated with unfavorable survival in lung adenocarcinoma. (Q36782607) (← links)
- Identification of potential biomarkers from microarray experiments using multiple criteria optimization (Q36804902) (← links)
- The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma. (Q37580157) (← links)
- Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions (Q38014834) (← links)
- New targets for the immunotherapy of colon cancer-does reactive disease hold the answer? (Q38089480) (← links)
- Allo-reactive T cells for the treatment of hematological malignancies (Q38636565) (← links)
- Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma (Q38828754) (← links)
- EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors (Q39160149) (← links)
- Human MageB2 Protein Expression Enhances E2F Transcriptional Activity, Cell Proliferation, and Resistance to Ribotoxic Stress (Q40430454) (← links)
- Lack of XAGE-1b and NY-ESO-1 in metastatic lymph nodes may predict the potential survival of stage III melanoma patients. (Q52800577) (← links)
- Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq Analysis (Q57186097) (← links)
- Identification of cancer/testis antigen 2 gene as a potential hepatocellular carcinoma therapeutic target by hub gene screening with topological analysis (Q90705899) (← links)
- Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma (Q91752028) (← links)